Factors Associated with Blood Pressure Control in Hypertensive Patients with Coronary Heart Disease: Evidence from the Chinese Cholesterol Education Program

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Xu, Dachun ^a   Chen, Wei ^a   Li, Xiankai ^a   Zhang, Yi ^a   Li, Xin ^a   Lei, Hou ^a   Wei, Yidong ^a   Li, Weiming ^a   Hu, Dayi ^a   Wedick, Nicole M ^c   Wang, Jinsong ^c,d   Xu, Yawei ^a   Li, Jue ^a,b   Ma, Yunsheng ^c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d YANGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; VERAPAMIL;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHINA; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OBESITY; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; CHINA; CHOLESTEROL; CORONARY DISEASE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC;

EID: 84877750252     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063135     Document Type: Article

References (24)

1. Yusuf S, Reddy S, Ounpuu S, Anand S, (2001) Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104: 2746-2753.
2. Wu Y, Huxley R, Li L, Anna V, Xie G, et al. (2008) Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 118: 2679-2686.
3. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, et al. (2006) The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 48: 385-391.
4. Fox KM, (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782-788.
5. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, et al. (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115: 2761-2788.
6. Hu D, Li J, Li X, (2008) Investigation of blood lipid levels and statin interventions in outpatients with coronary heart disease in China: the China Cholesterol Education Program (CCEP). Circ J 72: 2040-2045.
7. (2000) WHO Regional Office for the Western Pacific/International Association for the Study of Obesity/International Obesity Task Force. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney, Australia: Health Communications Australia.
8. Smith SC Jr, Clark LT, Cooper RS, Daniels SR, Kumanyika SK, et al. (2005) Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation 111: e134-139.
9. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17: 151-183.
10. Alberti KG, Zimmet PZ, (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.
11. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, et al. (2006) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113: e463-654.
12. Staessen JA, Wang JG, Thijs L, (2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358: 1305-1315.
13. Turnbull F, (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527-1535.
14. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, et al. (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. Jama 292: 2217-2225.
15. Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, et al. (2008) Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J 29: 3052-3060.
16. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC, (2011) Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124: 1046-1058.
17. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, et al. (2012) Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 308: 875-881.
18. Elisaf MS, Kalaitzidis RG, Goudevenos JA, Katsaraki AE, Sideris DA, et al. (1999) Blood pressure profile in patients with microvascular angina. Coron Artery Dis 10: 257-259.
19. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, et al. (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345: 790-797.
20. Cappuccio FP, MacGregor GA, (1994) The role of dietary sodium intake in the control of high blood pressure. A short review. Contrib Nephrol 106: 148-152.
21. Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, et al. (2000) Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 35: 592-599.
22. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, et al. (2000) Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102: 1503-1510.
23. de la Sierra A, Segura J, Gorostidi M, Banegas JR, de la Cruz JJ, et al. (2010) Diurnal blood pressure variation, risk categories and antihypertensive treatment. Hypertens Res 33: 767-771.
24. Krikler DM, Harris L, Rowland E, (1982) Calcium-channel blockers and beta blockers: advantages and disadvantages of combination therapy in chronic stable angina pectoris. Am Heart J 104: 702-708.